PATENT CLAIM ANALYSIS

Application Number: 15984935
Application Type: Utility
Filing Date: 2018-05
Publication Date: 2018-11
Patent Classification: ["435", "006140"]

Abstract:
The present invention is directed to methods for detecting a melanoma, methods for determining whether a melanoma is stable or progressive, methods for evaluating the extent of surgery resection in a subject having a melanoma, and methods for determining a response by a subject having a melanoma to a therapy.

Claim (Index 23):
A method for determining whether a melanoma in a subject is stable or progressive, comprising:\n determining the expression level of at least 29 biomarkers from a test sample from the subject by contacting the test sample with a plurality of agents specific to detect the expression of the at least 29 biomarkers, wherein the at least 29 biomarkers comprise ATL1, ATP6V0D, C1ORF21, CFLAR, CFLAR-AS1, CHP1, DDX55, DMD, DNAJC9, ENOSF1, FANCL, HJURP, HLA-DOA, HLA-DRA, HNRNPA3P1, IL23A, IQGAP1, LOC494127, LOC646471, LOH12CR, PBXIP1, RNF5, SERTAD2, SLC35G5, SPATS2L, TDRD7, TXK, YY2, and at least one housekeeping gene; normalizing the expression level of each of ATL1, ATP6V0D, C1ORF21, CFLAR, CFLAR-AS1, CHP1, DDX55, DMD, DNAJC9, ENOSF1, FANCL, HJURP, HLA-DOA, HLA-DRA, HNRNPA3P1, IL23A, IQGAP1, LOC494127, LOC646471, LOH12CR, PBXIP1, RNF5, SERTAD2, SLC35G5, SPATS2L, TDRD7, TXK, and YY2 to the expression level of the at least one housekeeping gene, thereby obtaining a normalized expression level of each of ATL1, ATP6V0D, C1ORF21, CFLAR, CFLAR-AS1, CHP1, DDX55, DMD, DNAJC9, ENOSF1, FANCL, HJURP, HLA-DOA, HLA-DRA, HNRNPA3P1, IL23A, IQGAP1, LOC494127, LOC646471, LOH12CR, PBXIP1, RNF5, SERTAD2, SLC35G5, SPATS2L, TDRD7, TXK, and YY2; inputting each normalized expression level into an algorithm to generate a score; comparing the score with a second predetermined cutoff value; and producing a report, wherein the report identifies that the melanoma is progressive when the normalized expression level is equal to or greater than the second predetermined cutoff value or identifies that the melanoma is stable when the normalized expression level is below the second predetermined cutoff value, wherein the second predetermined cutoff value is 50 on a scale of 0 to 100.

Metadata:
- Claim Count in Document: 46.0
- Percentile: 93.0
- Lexical Diversity: 1.74194
- Patent Class: 435.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['14855229', '14357191', '14405739', '14433681', '13580571']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.4994638746830026
- 35 USC 102 Novelty (BERT): 0.4967741562980309
- Combined Prediction Score: 0.4991949028445054
- Mean Citation Score: 157.20472
- Max Citation Score: 170.31271
- Similarity Product: 106.5686617901075

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 0

Dataset: test